How can ophthalmologists better educate patients about the severity of DME progression?
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
FDA approves expanded label for fluocinolone acetonide intravitreal implant
Unity Biotechnology Inc appoints Yehia Hashad, MD, to the board of directors and science committee
Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment
PDS implant matches monthly injections in efficacy in DME treatment